Vujačić Nataša, Paunović Ivan, Diklić Aleksandar, Živaljević Vladan, Slijepčević Nikola, Kalezić Nevena, Stojković Mirjana, Stojanović Miloš, Beleslin Biljana, Žarković Miloš, Ćirić Jasmina
Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade.
Clinical Center of Serbia, Center of Endocrine Surgery, Belgrade.
J Med Biochem. 2020 Jan 23;39(2):240-248. doi: 10.2478/jomb-2019-0035.
Primary aldosteronism (PA) is associated with increased prevalence of metabolic disorders (impaired glucose and lipid metabolism and insulin resistance), but also with more frequent cardiovascular, renal and central nervous system complications.
Biochemical and clinical parameters were retrospectively analysed for 40 patients with PA caused by aldosterone-producing adenoma (APA) and compared to the control groups of 40 patients with nonfunctioning adrenal adenoma (NFA) and essential hypertension (HT), and 20 patients with adrenal Cushing syndrome (CS) or subclinical CS (SCS).
Systolic, diastolic and mean arterial blood pressures were significantly higher in the PA group (p=0.004; p=0.002; p=0.001, respectively) than in NFA+HT group. PA patients had longer hypertension history (p=0.001) than patients with hypercorticism and all had hypokalaemia. This group showed the smallest mean tumour diameter (p<0.001). The metabolic syndrome was significantly less common in the PA group (37.5% vs. 70% in CS+SCS and 65% in NFA+HT group; p=0.015), although there was no significant difference in any of the analysed metabolic parameters between groups. PA group was found to have the most patients with glucose intolerance (81.8%), although the difference was not significant. The mean BMI for all three groups was in the overweight range. Patients with PA had higher microalbuminuria and a higher tendency for cardiovascular, renal and cerebrovascular events, but the difference was not significant.
Our results support the importance of the early recognition of primary aldosteronism on the bases of clinical presentation, as well as an increased screening intensity.
原发性醛固酮增多症(PA)与代谢紊乱(糖脂代谢受损及胰岛素抵抗)患病率增加相关,同时也与更频繁的心血管、肾脏及中枢神经系统并发症有关。
对40例由醛固酮瘤(APA)引起的PA患者的生化及临床参数进行回顾性分析,并与40例无功能肾上腺腺瘤(NFA)和原发性高血压(HT)患者以及20例肾上腺库欣综合征(CS)或亚临床库欣综合征(SCS)患者的对照组进行比较。
PA组的收缩压、舒张压及平均动脉压显著高于NFA + HT组(分别为p = 0.004;p = 0.002;p = 0.001)。PA患者的高血压病史长于皮质醇增多症患者(p = 0.001),且均有低钾血症。该组的平均肿瘤直径最小(p < 0.001)。PA组代谢综合征的发生率显著低于CS + SCS组(37.5% 对70%)和NFA + HT组(65%)(p = 0.015),尽管各组间分析的任何代谢参数均无显著差异。PA组糖耐量异常患者最多(81.8%),但差异无统计学意义。三组的平均体重指数均处于超重范围。PA患者的微量白蛋白尿较高,发生心血管、肾脏及脑血管事件的倾向也较高,但差异无统计学意义。
我们的结果支持基于临床表现早期识别原发性醛固酮增多症的重要性,以及提高筛查强度。